Irwin Naturals Bringing Its Household Name Brand to the Psychedelic Mental Health SpaceTryp Therapeutics Announces Inclusion in AdvisorShares Psychedelics ETFMindMed and Liechti Lab Provide Results from their Psilocybin R&D CollaborationPsyched Wellness Announces Inclusion in AdvisorShares Psychedelics Exchange Traded Fund (ETF)Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Eating DisordersPsyched Wellness Initiates a Clinical Sleep Study on Humans for a Structure/Function Claim For AME-1Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

HAVN Life Sciences Is Off To A Great Start Out Of The Gate

Sep 16, 2020 • 7:46 AM EDT
4 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Last week, Havn Life Sciences Inc. (CSE:HAVN) commenced trading on the Canadian Securities Exchange (CSE) under the ticker symbol HAVN. The biotech company has been focused on the development of standardized psychoactive compounds that are derived from plants and fungi for use in research and is an opportunity that we are excited about.

When it comes to the psychedelic therapy market, one of the most important aspects of any business is the management team. Havn Life’s leadership team is focused on developing standardizing supply chains for research and  future medical purposes. This is a unique and exciting approach to the vertical.

Havn Life represents a multi-faceted growth opportunity and is also focused on the development of natural healthcare products that contain novel and natural psychoactive compounds and are designed to unlock human potential. The management team has been working tirelessly on a series of growth initiatives that include product formulation of effective novel psychoactive compounds as well as the development of a state-of-the-art mycology extraction lab.

Havn Life is comprised of two divisions (Havn Labs and Havn Retail) that can create value for each other and are bullish on the amount of synergies that can be found between them. Through Havn Labs, the company operates a licensed laboratory that is focused on the advancement and formulation of regulated psychoactive compounds. The division operates out of a state-of-the-art facility that is based at UBC and is used for advanced formulation development, standardization testing and quality control. Havn Life plans to sell its formulations through Havn Retail and we will monitor how the team is able to execute on this.

Led by a Diverse Management Team with a Proven Track Record

The strength of Havn Life’s management team is a key aspect of the story and we are favorable on the collective expertise of the team. The company has a team that has significant experience in the pharmaceuticals, technology and cannabis industries, and we find this to be significant.

Havn Life is led by Co-CEOs, Tim Moore and Susan Chapelle, that have diverse expertise and bring impressive experience to the structure of the leadership team. Tim who has over 30 years’ experience in Fortune 500 leadership roles in North America and formerly served as CEO of Green Growth Brands. Susan has 25 years of leadership experience as a researcher, as well as in the health, technology, non-profit, and private sectors in Canada.

From Dr. Ivan Casselman (Ph.D., FLS) serves as Havn Life’s Chief Psychedelic Officer and is an experienced formulation chemist with a strong foundation in nutraceutical formulation and product development. Gary Leong serves as Havn Life’s Chief Scientific Officer (CSO) and was the former CSO at Jamieson Laboratories for 14 years. He was also the CSO at Aphria for five years and has a thorough understanding of formulation development and the natural health products market. Ivan and Gary add to the team impressive resumes from a science standpoint and expect them to play an important role in the success of the operation.

Vic Neufeld serves as a director on the Havn Life board of directors and was previously the CEO of Jamieson Laboratories for 21 years, Canada’s largest manufacturer and distributor of natural vitamins and minerals. He played a key role in the success of one of the largest Canadian cannabis producers and we are favorable on the experience that he brings to the team.

An Emerging Growth Story

Havn Life is in the final stages of product development and expects to have products available in nutraceutical retailers in Q1 2020. We are bullish on the growth prospects that are associated with this timeline and will monitor how the management team is able to drive the story forward.

Over the next year, we expect Havn Life to record substantial developments and are bullish on the amount of value and the amount of synergies that can be generated between its divisions. We believe that the opportunity is flying under the radar and expect this to change as the company continues to execute on previously announced initiatives.

If you are interested in learning more about Havn Life, please send an email to to be added to our distribution list.









Pursuant to an agreement between StoneBridge Partners LLC and HAVN Life Sciences we have been hired for a period of 180 days beginning June 1, 2020 and ending December 1, 2020 to publicly disseminate information about (HAVN) including on the Website and other media including Facebook and Twitter. We are being paid $7,500 per month (HAVN) for or were paid “0” shares of restricted common shares. We own zero shares of (HAVN), which we purchased in the open market. We plan to sell the “ZERO” shares of (HAVN) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (HAVN) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Share Share - Facebook Share - Twitter


Authored By

Michael Berger


Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.